Departamento
HOSPITAL UNIVERSITARIO RUBER
Publicaciones (59) Publicaciones en las que ha participado algún/a investigador/a
2018
-
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer
Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221
-
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
-
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
Annals of Oncology, Vol. 29, Núm. 1, pp. 170-177
-
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Annals of Oncology, Vol. 29, Núm. 3, pp. 661-668
-
Anastomosis microquirúrgica
Cirugía oral y maxilofacial: atlas de procedimientos y técnicas quirúrgicas (Editorial Médica Panamericana), pp. 891-896
-
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824
-
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826
-
Breast cancer in 2017: Spurring science, marking progress, and influencing history
Nature Reviews Clinical Oncology, Vol. 15, Núm. 2, pp. 79-80
-
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
European Journal of Cancer, Vol. 103, pp. 147-154
-
CXCR4 antagonists for treatment of breast cancer
Oncotarget
-
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357
-
Complete resolution of dysphagia after sequential Polyflex™ stenting in a case of recurrent anastomotic stenosis in an adult with congenital esophageal atresia
Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 12, pp. 826-829
-
Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
-
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)
Clinical and Translational Oncology
-
Corrigendum: Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle (Annals of Oncology (2014) 25 (1729–1735) DOI: 10.1093/annonc/mdu239)
Annals of Oncology
-
Corrigendum: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab [Ann Oncol., 28, (2017) (761-768)] DOI: 10.1093/annonc/mdw695
Annals of Oncology
-
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy
Melanoma Research, Vol. 28, Núm. 3, pp. 195-203
-
El urólogo del futuro y las nuevas tecnologías
Archivos Espanoles de Urologia, Vol. 71, Núm. 1, pp. 142-149